التفاصيل البيبلوغرافية
| العنوان: |
Clinical outcomes of high‐intensity doses of atorvastatin in patients with acute coronary syndrome: A retrospective cohort study using real‐world data. |
| المؤلفون: |
Rahhal, Alaa, Khir, Fadi, Aljundi, Amer Hussien, AlAhmad, Yaser, Alzaeem, Hakam, Habra, Masa, Al‐Shekh, Israa, Mahfouz, Ahmed, Awaisu, Ahmed, Al‐Yafei, Sumaya, Arabi, Abdul Rahman |
| المصدر: |
British Journal of Clinical Pharmacology; Apr2021, Vol. 87 Issue 4, p2043-2052, 10p |
| مصطلحات موضوعية: |
ACUTE coronary syndrome, TREATMENT effectiveness, ATORVASTATIN, COHORT analysis, HEPATOTOXICOLOGY |
| مصطلحات جغرافية: |
QATAR |
| مستخلص: |
Aims: To compare the effectiveness and safety of 2 high‐intensity atorvastatin doses (40 mg vs 80 mg) among acute coronary syndrome (ACS) patients. Methods: This retrospective observational cohort study using real‐world data included patients admitted with ACS to the Heart Hospital in Qatar between 1 January 2017 and 31 December 2018. The primary endpoint was a composite of cardiovascular disease‐associated death, nonfatal ACS and nonfatal stroke. Cox proportional hazard regression analysis was used to determine the association between the 2 high‐intensity atorvastatin dosing regimens and the primary outcome at 1 month and 12 months postdischarge. Results: Of the 626 patients included in the analyses, 475 (75.9%) received atorvastatin 40 mg, while 151 (24.1%) received atorvastatin 80 mg following ACS. Most of the patients were Asian (73%), male (97%) with a mean age of 50 years and presented with ST‐elevation myocardial infarction (60%). The incidence of the primary effectiveness outcome did not differ between the atorvastatin 40‐and 80‐mg groups at 1 month (0.8 vs 1.3%; adjusted hazard ratio = 0.59, 95% confidence interval 0.04–8.13, P =.690) and at 12 months (3.2 vs 4%; adjusted hazard ratio = 0.57, 95% confidence interval 0.18–1.80, P =.340). Similarly, the use of the 2 doses of atorvastatin resulted in comparable safety outcomes, including liver toxicity, myopathy and rhabdomyolysis with an event rate of <1% in both groups. Conclusion: The use of atorvastatin 40 mg in comparison to atorvastatin 80 mg in patients with ACS resulted in similar cardiovascular effectiveness and safety outcomes. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Clinical Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder